Revance Therapeutics Under Scrutiny from Shareholders
Glancy Prongay & Murray LLP (GPM), a prominent name in securities law, has initiated an investigation into Revance Therapeutics, Inc. (NASDAQ: RVNC) on behalf of its investors. The investigation focuses on the company's potential breaches of federal securities laws.
Understand the Implications of the Investigation
If you've experienced financial loss due to your investments in Revance, GPM encourages you to come forward and explore your options for recovering losses. Submitting your information to a law firm specializing in shareholder rights can be the first key step in addressing your concerns.
Recent Developments Affecting Revance
On a recent filing with the U.S. Securities and Exchange Commission, Revance disclosed serious allegations regarding breaches of their agreement with Teoxane SA. The company was notified to remedy these breaches, which included exceeding buffer stock limits and unmet promotional efforts as required by their contract.
Stock Market Reaction
This troubling news had an immediate impact on Revance's stock valuation, with a noticeable decline following the announcement. On the day of the disclosure, the share price fell sharply by 7.66%, closing at $5.37.
Seeking Whistleblowers
In light of the seriousness of these allegations, GPM is also urging anyone with non-public information about Revance to consider participating in the investigation. Individuals who provide original information may qualify for rewards under the SEC Whistleblower Program, adding another incentive for accountability.
About Glancy Prongay & Murray LLP
GPM has carved a reliable niche in the realm of investor advocacy and consumer protection. Recognized as a leader in securities litigation, the firm has been consistently ranked among the top firms for successful outcomes in class-action lawsuits. With a seasoned team of nearly 40 attorneys across several offices, GPM has recovered billions for its clients while addressing various forms of corporate misconduct.
Stay Informed with GPM
For ongoing updates regarding Revance Therapeutics and other relevant news, investors are encouraged to follow GPM on social media platforms like LinkedIn, Twitter, and Facebook. Staying informed can be crucial for making timely decisions regarding your investments.
Frequently Asked Questions
What triggered the investigation into Revance Therapeutics?
The investigation was initiated due to potential violations of federal securities laws following Revance's disclosures about compliance issues with their distribution agreement.
How can investors report their losses related to Revance?
Investors can submit their contact details to GPM for consultation on potential claims related to their financial losses.
What was the market reaction to Revance's recent announcement?
The announcement resulted in a significant drop in Revance's stock price, reflecting investor concerns over the company's compliance issues.
Who can participate in the SEC Whistleblower Program?
Individuals with original information about the investigation or Revance's operations may qualify for the SEC Whistleblower Program, which offers potential rewards for significant contributions.
What accolades has Glancy Prongay & Murray LLP received?
GPM has been consistently ranked among the top firms in securities litigation, achieving notable settlements and being recognized as a leader in complex class action cases.
